Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SAR442168 versus teriflunomide in relapsing multiple sclerosis
NL-OMON53998Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tolebrutinib in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoints: Annualized adjudicated relapse rate and Time to onset of 6-month confirmed disability progression. Started Feb 2023; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON53998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53998.